---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-011802"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2025-08-28T23:59:59+00:00"
generated_at: "2026-05-17T09:30:58.732529+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Xilio Therapeutics receives second Nasdaq deficiency letter for low stockholders' equity; bid price also non-compliant

## Summary
- Reported stockholders' equity of $7.069M as of June 30, 2025, below $10M minimum required for Nasdaq Global Select Market.
- Company has 45 days (until Oct 6, 2025) to submit a compliance plan; Nasdaq may grant up to 180-day extension.
- Also remains out of compliance with $1.00 minimum bid price requirement, initial cure period expires Oct 1, 2025.
- No immediate effect on listing; company may also seek transfer to Nasdaq Capital Market.

## SEC filing metadata
- accession: 0001558370-25-011802
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2025-08-28T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000155837025011802/0001558370-25-011802-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000155837025011802/xlo-20250822x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-011802
- JSON: https://secwatch.observer/filing/0001558370-25-011802.json
- Plain text: https://secwatch.observer/filing/0001558370-25-011802.txt

## Key facts
- Listing & Compliance Notices
  Xilio Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5450(b)(1)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5450(b)(1)(A)
  source text: August 22, 2025, Xilio Therapeutics, Inc. (the “Company”) received a deficiency letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that it is not in compliance with the requirement to maintain a minimum of $10.0 million in stockholders’ equity, as required by Nasdaq Listing Rule 5450(b)(1)(A) for continued listing on The Nasdaq Global Select Market. As stated in the Letter, the Company reported stockholders’ equity of $7,069,000 in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840233/000155837025011802/0001558370-25-011802-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.